Oruka Therapeutics (ORKA) Amortization of Deferred Charges (2019 - 2020)

Oruka Therapeutics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $132000.0 for Q3 2025.

• In Q3 2025, Amortization of Deferred Charges rose 116.39% year-over-year to $132000.0; the TTM figure through Sep 2025 stood at $197000.0 (up 131.76% YoY), while the FY2023 annual figure was $96000.0, up 2.13% from the prior year.
• Amortization of Deferred Charges for Q3 2025 stood at $132000.0, up from $61000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $132000.0 in Q3 2025, with the low at -$12000.0 in Q2 2024.
• The 5-year median for Amortization of Deferred Charges is $23000.0 (2021), against an average of $28875.0.
• Peak annual rise in Amortization of Deferred Charges reached 134.62% in 2024, while the deepest fall reached 148.0% in 2024.
• Oruka Therapeutics' Amortization of Deferred Charges stood at $23000.0 in 2021, then climbed by 4.35% to $24000.0 in 2022, then fell by 16.67% to $20000.0 in 2023, then surged by 205.0% to $61000.0 in 2024, then jumped by 116.39% to $132000.0 in 2025.
• Business Quant data shows ORKA's Amortization of Deferred Charges at $132000.0 in Q3 2025, $61000.0 in Q3 2024, and -$12000.0 in Q2 2024.